Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)
For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss an...
Gespeichert in:
| Veröffentlicht in: | Strahlentherapie und Onkologie 2024-03, Vol.200 (3), p.181-187 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 187 |
|---|---|
| container_issue | 3 |
| container_start_page | 181 |
| container_title | Strahlentherapie und Onkologie |
| container_volume | 200 |
| creator | Koerber, S. A. Höcht, S. Aebersold, D. Albrecht, C. Boehmer, D. Ganswindt, U. Schmidt-Hegemann, N.-S. Hölscher, T. Mueller, A.-C. Niehoff, P. Peeken, J. C. Pinkawa, M. Polat, B. Spohn, S. K. B. Wolf, F. Zamboglou, C. Zips, D. Wiegel, T. |
| description | For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach. |
| doi_str_mv | 10.1007/s00066-023-02193-4 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10876748</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2928583635</sourcerecordid><originalsourceid>FETCH-LOGICAL-c2694-f9f375e9ce79eda8aff260afba90545d9bb00d506092ed1b5f5b64be19baa95f3</originalsourceid><addsrcrecordid>eNp9kU1uFDEQRi1ERCaBC7BAXrLpUG7b3e1VhCL-pCjJAiQ2yKp2lycd9diD3TPS7DgEB-AsHIWTYDIhgk0Wlhf1vs9WPcaeCzgRAO2rDABNU0EtyxFGVuoRWwglTQXGfH7MFiBaU7VCd4fsKOcbANEoo56wQ9nVrRRSL9iXqxTzjDNxh8FR4hgGThO5edwSD3HAiSccRpzHGPh8TQnXO-5j4u4CbuH1Bfz69h1__gi0LXkKwxiWPM8x7U6fsgOPU6Znd_cx-_T2zcez99X55bsPZ6_PK1c3RlXeeNlqMo5aQwN26H3dAPoeDWilB9P3AIOGBkxNg-i1132jehKmRzTay2N2uu9db_oVDY7CnHCy6zSuMO1sxNH-PwnjtV3GrRXQtU2rutLw8q4hxa8byrNdjdnRNGGguMm2NnWnO9lIXdB6j7qyupzI378jwP4RY_dibBFjb8VYVUIv_v3hfeSviQLIPZDLKCwp2Zu4SaFs7aHa3wmanMQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2928583635</pqid></control><display><type>article</type><title>Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)</title><source>MEDLINE</source><source>Springer Nature - Complete Springer Journals</source><creator>Koerber, S. A. ; Höcht, S. ; Aebersold, D. ; Albrecht, C. ; Boehmer, D. ; Ganswindt, U. ; Schmidt-Hegemann, N.-S. ; Hölscher, T. ; Mueller, A.-C. ; Niehoff, P. ; Peeken, J. C. ; Pinkawa, M. ; Polat, B. ; Spohn, S. K. B. ; Wolf, F. ; Zamboglou, C. ; Zips, D. ; Wiegel, T.</creator><creatorcontrib>Koerber, S. A. ; Höcht, S. ; Aebersold, D. ; Albrecht, C. ; Boehmer, D. ; Ganswindt, U. ; Schmidt-Hegemann, N.-S. ; Hölscher, T. ; Mueller, A.-C. ; Niehoff, P. ; Peeken, J. C. ; Pinkawa, M. ; Polat, B. ; Spohn, S. K. B. ; Wolf, F. ; Zamboglou, C. ; Zips, D. ; Wiegel, T.</creatorcontrib><description>For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.</description><identifier>ISSN: 0179-7158</identifier><identifier>EISSN: 1439-099X</identifier><identifier>DOI: 10.1007/s00066-023-02193-4</identifier><identifier>PMID: 38273135</identifier><language>eng</language><publisher>Berlin/Heidelberg: Springer Berlin Heidelberg</publisher><subject>Humans ; Male ; Medicine ; Medicine & Public Health ; Neoplasm Recurrence, Local ; Oncology ; Positron Emission Tomography Computed Tomography - methods ; Prostate-Specific Antigen ; Prostatic Neoplasms - radiotherapy ; Radiation Oncology ; Radiotherapy ; Review ; Review Article</subject><ispartof>Strahlentherapie und Onkologie, 2024-03, Vol.200 (3), p.181-187</ispartof><rights>The Author(s) 2024</rights><rights>2024. The Author(s).</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c2694-f9f375e9ce79eda8aff260afba90545d9bb00d506092ed1b5f5b64be19baa95f3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s00066-023-02193-4$$EPDF$$P50$$Gspringer$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s00066-023-02193-4$$EHTML$$P50$$Gspringer$$Hfree_for_read</linktohtml><link.rule.ids>230,314,776,780,881,27903,27904,41467,42536,51297</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38273135$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Koerber, S. A.</creatorcontrib><creatorcontrib>Höcht, S.</creatorcontrib><creatorcontrib>Aebersold, D.</creatorcontrib><creatorcontrib>Albrecht, C.</creatorcontrib><creatorcontrib>Boehmer, D.</creatorcontrib><creatorcontrib>Ganswindt, U.</creatorcontrib><creatorcontrib>Schmidt-Hegemann, N.-S.</creatorcontrib><creatorcontrib>Hölscher, T.</creatorcontrib><creatorcontrib>Mueller, A.-C.</creatorcontrib><creatorcontrib>Niehoff, P.</creatorcontrib><creatorcontrib>Peeken, J. C.</creatorcontrib><creatorcontrib>Pinkawa, M.</creatorcontrib><creatorcontrib>Polat, B.</creatorcontrib><creatorcontrib>Spohn, S. K. B.</creatorcontrib><creatorcontrib>Wolf, F.</creatorcontrib><creatorcontrib>Zamboglou, C.</creatorcontrib><creatorcontrib>Zips, D.</creatorcontrib><creatorcontrib>Wiegel, T.</creatorcontrib><title>Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)</title><title>Strahlentherapie und Onkologie</title><addtitle>Strahlenther Onkol</addtitle><addtitle>Strahlenther Onkol</addtitle><description>For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.</description><subject>Humans</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Neoplasm Recurrence, Local</subject><subject>Oncology</subject><subject>Positron Emission Tomography Computed Tomography - methods</subject><subject>Prostate-Specific Antigen</subject><subject>Prostatic Neoplasms - radiotherapy</subject><subject>Radiation Oncology</subject><subject>Radiotherapy</subject><subject>Review</subject><subject>Review Article</subject><issn>0179-7158</issn><issn>1439-099X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><recordid>eNp9kU1uFDEQRi1ERCaBC7BAXrLpUG7b3e1VhCL-pCjJAiQ2yKp2lycd9diD3TPS7DgEB-AsHIWTYDIhgk0Wlhf1vs9WPcaeCzgRAO2rDABNU0EtyxFGVuoRWwglTQXGfH7MFiBaU7VCd4fsKOcbANEoo56wQ9nVrRRSL9iXqxTzjDNxh8FR4hgGThO5edwSD3HAiSccRpzHGPh8TQnXO-5j4u4CbuH1Bfz69h1__gi0LXkKwxiWPM8x7U6fsgOPU6Znd_cx-_T2zcez99X55bsPZ6_PK1c3RlXeeNlqMo5aQwN26H3dAPoeDWilB9P3AIOGBkxNg-i1132jehKmRzTay2N2uu9db_oVDY7CnHCy6zSuMO1sxNH-PwnjtV3GrRXQtU2rutLw8q4hxa8byrNdjdnRNGGguMm2NnWnO9lIXdB6j7qyupzI378jwP4RY_dibBFjb8VYVUIv_v3hfeSviQLIPZDLKCwp2Zu4SaFs7aHa3wmanMQ</recordid><startdate>20240301</startdate><enddate>20240301</enddate><creator>Koerber, S. A.</creator><creator>Höcht, S.</creator><creator>Aebersold, D.</creator><creator>Albrecht, C.</creator><creator>Boehmer, D.</creator><creator>Ganswindt, U.</creator><creator>Schmidt-Hegemann, N.-S.</creator><creator>Hölscher, T.</creator><creator>Mueller, A.-C.</creator><creator>Niehoff, P.</creator><creator>Peeken, J. C.</creator><creator>Pinkawa, M.</creator><creator>Polat, B.</creator><creator>Spohn, S. K. B.</creator><creator>Wolf, F.</creator><creator>Zamboglou, C.</creator><creator>Zips, D.</creator><creator>Wiegel, T.</creator><general>Springer Berlin Heidelberg</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20240301</creationdate><title>Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?</title><author>Koerber, S. A. ; Höcht, S. ; Aebersold, D. ; Albrecht, C. ; Boehmer, D. ; Ganswindt, U. ; Schmidt-Hegemann, N.-S. ; Hölscher, T. ; Mueller, A.-C. ; Niehoff, P. ; Peeken, J. C. ; Pinkawa, M. ; Polat, B. ; Spohn, S. K. B. ; Wolf, F. ; Zamboglou, C. ; Zips, D. ; Wiegel, T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c2694-f9f375e9ce79eda8aff260afba90545d9bb00d506092ed1b5f5b64be19baa95f3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Humans</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Neoplasm Recurrence, Local</topic><topic>Oncology</topic><topic>Positron Emission Tomography Computed Tomography - methods</topic><topic>Prostate-Specific Antigen</topic><topic>Prostatic Neoplasms - radiotherapy</topic><topic>Radiation Oncology</topic><topic>Radiotherapy</topic><topic>Review</topic><topic>Review Article</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Koerber, S. A.</creatorcontrib><creatorcontrib>Höcht, S.</creatorcontrib><creatorcontrib>Aebersold, D.</creatorcontrib><creatorcontrib>Albrecht, C.</creatorcontrib><creatorcontrib>Boehmer, D.</creatorcontrib><creatorcontrib>Ganswindt, U.</creatorcontrib><creatorcontrib>Schmidt-Hegemann, N.-S.</creatorcontrib><creatorcontrib>Hölscher, T.</creatorcontrib><creatorcontrib>Mueller, A.-C.</creatorcontrib><creatorcontrib>Niehoff, P.</creatorcontrib><creatorcontrib>Peeken, J. C.</creatorcontrib><creatorcontrib>Pinkawa, M.</creatorcontrib><creatorcontrib>Polat, B.</creatorcontrib><creatorcontrib>Spohn, S. K. B.</creatorcontrib><creatorcontrib>Wolf, F.</creatorcontrib><creatorcontrib>Zamboglou, C.</creatorcontrib><creatorcontrib>Zips, D.</creatorcontrib><creatorcontrib>Wiegel, T.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Strahlentherapie und Onkologie</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Koerber, S. A.</au><au>Höcht, S.</au><au>Aebersold, D.</au><au>Albrecht, C.</au><au>Boehmer, D.</au><au>Ganswindt, U.</au><au>Schmidt-Hegemann, N.-S.</au><au>Hölscher, T.</au><au>Mueller, A.-C.</au><au>Niehoff, P.</au><au>Peeken, J. C.</au><au>Pinkawa, M.</au><au>Polat, B.</au><au>Spohn, S. K. B.</au><au>Wolf, F.</au><au>Zamboglou, C.</au><au>Zips, D.</au><au>Wiegel, T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO)</atitle><jtitle>Strahlentherapie und Onkologie</jtitle><stitle>Strahlenther Onkol</stitle><addtitle>Strahlenther Onkol</addtitle><date>2024-03-01</date><risdate>2024</risdate><volume>200</volume><issue>3</issue><spage>181</spage><epage>187</epage><pages>181-187</pages><issn>0179-7158</issn><eissn>1439-099X</eissn><abstract>For prostate cancer, the role of elective nodal irradiation (ENI) for cN0 or pN0 patients has been under discussion for years. Considering the recent publications of randomized controlled trials, the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) aimed to discuss and summarize the current literature. Modern trials have been recently published for both treatment-naïve patients (POP-RT trial) and patients after surgery (SPPORT trial). Although there are more reliable data to date, we identified several limitations currently complicating the definitions of general recommendations. For patients with cN0 (conventional or PSMA-PET staging) undergoing definitive radiotherapy, only men with high-risk factors for nodal involvement (e.g., cT3a, GS ≥ 8, PSA ≥ 20 ng/ml) seem to benefit from ENI. For biochemical relapse in the postoperative situation (pN0) and no PSMA imaging, ENI may be added to patients with risk factors according to the SPPORT trial (e.g., GS ≥ 8; PSA > 0.7 ng/ml). If PSMA-PET/CT is negative, ENI may be offered for selected men with high-risk factors as an individual treatment approach.</abstract><cop>Berlin/Heidelberg</cop><pub>Springer Berlin Heidelberg</pub><pmid>38273135</pmid><doi>10.1007/s00066-023-02193-4</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0179-7158 |
| ispartof | Strahlentherapie und Onkologie, 2024-03, Vol.200 (3), p.181-187 |
| issn | 0179-7158 1439-099X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10876748 |
| source | MEDLINE; Springer Nature - Complete Springer Journals |
| subjects | Humans Male Medicine Medicine & Public Health Neoplasm Recurrence, Local Oncology Positron Emission Tomography Computed Tomography - methods Prostate-Specific Antigen Prostatic Neoplasms - radiotherapy Radiation Oncology Radiotherapy Review Review Article |
| title | Prostate cancer and elective nodal radiation therapy for cN0 and pN0—a never ending story?: Recommendations from the prostate cancer expert panel of the German Society of Radiation Oncology (DEGRO) |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T14%3A17%3A17IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Prostate%20cancer%20and%20elective%20nodal%20radiation%20therapy%20for%20cN0%20and%20pN0%E2%80%94a%C2%A0never%20ending%20story?:%20Recommendations%20from%20the%20prostate%20cancer%20expert%20panel%20of%20the%20German%20Society%20of%20Radiation%20Oncology%20(DEGRO)&rft.jtitle=Strahlentherapie%20und%20Onkologie&rft.au=Koerber,%20S.%20A.&rft.date=2024-03-01&rft.volume=200&rft.issue=3&rft.spage=181&rft.epage=187&rft.pages=181-187&rft.issn=0179-7158&rft.eissn=1439-099X&rft_id=info:doi/10.1007/s00066-023-02193-4&rft_dat=%3Cproquest_pubme%3E2928583635%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2928583635&rft_id=info:pmid/38273135&rfr_iscdi=true |